Suscribirse

Early-phase dose articulation trials are underutilized for post-stroke motor recovery: A systematic scoping review - 09/02/22

Doi : 10.1016/j.rehab.2021.101487 
Emily J. Dalton a, Leonid Churilov b, Natasha A. Lannin c, d, Dale Corbett e, Bruce C.V. Campbell f, Kathryn S. Hayward g,
a Melbourne School of Health Sciences, University of Melbourne, Heidelberg, Australia 
b Melbourne Medical School, University of Melbourne, Parkville, Australia 
c Department of Neurosciences, Central Clinical School, Monash University, Melbourne, Australia 
d Alfred Health, Melbourne, Australia 
e Cellular & Molecular Medicine and Canadian Partnership for Stroke Recovery, University of Ottawa, Canada 
f Department of Medicine and Neurology, Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia 
g Melbourne School of Health Sciences and Florey Institute of Neuroscience and Mental Health, University of Melbourne, 245 Burgundy Street, 3084 Heidelberg, Australia 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

To enable development of effective interventions, there is a need to complete systematic early-phase dose articulation research. This scoping review aimed to synthesize dose articulation research of behavioral motor interventions for stroke recovery.

Methods

MEDLINE and EMBASE were systematically searched for dose articulation studies. Preclinical experiments and adult clinical trials were classified based on the discovery pipeline and analyzed to determine which dose dimensions were articulated (time, scheduling or intensity) and how they were investigated (unidimensional vs multidimensional approach). Reporting of dose, safety and efficacy outcomes were summarized. The intervention description, risk of bias, and quality was appraised.

Results

We included 41 studies: 3 of preclinical dose preparation (93 rodents), 2 Phase I dose ranging (21 participants), 9 Phase IIA dose screening (198 participants), and 27 Phase IIB dose finding (1879 participants). All studies adopted a unidimensional approach. Time was the most frequent dimension investigated (53%), followed by intensity (29%), and scheduling (18%). Overall, 95% studies reported an efficacy outcome; however, only 65% reported dose and 45% reported safety. Across studies, 61% were at high risk of bias, and the average percentage reporting of intervention description and quality was 61% and 67%, respectively.

Conclusion

This review highlights a need to undertake more high-quality, early-phase studies that systematically articulate intervention doses from a multidimensional perspective in the field of behavioral motor stroke recovery. To address this gap, we need to invest in adapting early phase trial designs, especially Phase I, to support multidimensional dose articulation.

El texto completo de este artículo está disponible en PDF.

Keywords : Stroke rehabilitation, Clinical trial, Translational medical research, Animal model, Neuroscience, Dosing


Esquema


© 2021  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 65 - N° 1

Artículo 101487- janvier 2022 Regresar al número
Artículo precedente Artículo precedente
  • Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews
  • Anne-Mette Hedeager Momsen, Lisbeth Ørtenblad, Thomas Maribo
| Artículo siguiente Artículo siguiente
  • Equations for estimating the oxygen cost of walking in stroke patients: Systematic review
  • M. Compagnat, J.C. Daviet, A. Perrochon, J.Y. Salle, S. Mandigout

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.